This is the Hackathon Secretariat.Autumn has deepened, and the wind has started to feel cold. November 6th is the day the ban ...
Daily Excelsior on MSN
DDC Doda reviews progress of HADP, JKCIP
Excelsior Correspondent DODA, Nov 5: District Development Commissioner (DDC) Doda Krishan Lal today chaired a review meeting ...
CLN-049 is also being studied in a Phase 1/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and PD of IV-administered CLN-049 in ...
The progress report meeting is next week, yet the materials are still blank. The figures from the team members haven't arrived, and it hasn't been decided how to report on delayed tasks. You end up ...
Miniature Wonders is presented with a $100,000 check to help fund major project updates for the developing outdoor attraction ...
The Punch on MSN
Lagos seeks investment in cooperative-led Louisville project
Lagos State Director of Cooperatives, Dr Adeyemi Adeyinka, has praised the ambition behind Louisville, a mixed-use development by TotalEnergies Staff Housing Cooperative Multipurpose Society Ltd, ...
From 25 Launches a Year to 456. A New Free Presentation Reveals What Elon Musk Plans to Launch Next.
SpaceX wants approval to fly Starship nearly every day from South Texas. James Altucher says Musk is already “TWO decades ahead” of his rivals in the race to put AI in orbit.Baltimore, MD, Nov. 04, ...
BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines ...
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress ...
Arizona’s 340-MW Snowflake wind project is on hold while developers reconsider its location near homes and national forest ...
Many Peaks Minerals Limited (ASX:MPK) has released an October 2026 investor presentation disclosing a maiden Mineral Resource ...
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in aut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results